PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

Valerie COMBARET et al.

Application No.: 10/572,905

Filed: March 21, 2006 Docket No.: 127189

For: METHOD FOR NEUROBLASTOMA DIAGNOSIS/PROGNOSIS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- 1. This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date of this non-CPA application, OR (b) before the mailing date of a first Office Action on the merits in the present application. No certification or fee is required.
- 2. Relevance of one or more non-English language reference is discussed in the present specification. See References 13-19, 22, 23, 26 and 27.
- 3. One or more reference cited herein was cited in the International Search Report. An English language version of the International Search Report is attached for the Examiner's information. See References 34-42.
- 4. In accordance with 37 CFR §1.98(a)(2)(ii), copies of any U.S. patents and patent application publications are not attached.

 \boxtimes

5. An English language Abstract of one or more non-English language reference is attached hereto. See References <u>15-19</u>, <u>22-23</u> and <u>26-27</u>.

Respectfully submitted,

William P. Berridge Registration No. 30,024

Randi B. Isaacs Registration No. 56,046

WPB:RBI/emt

Date: July 28, 2006

OLIFF & BERRIDGE, PLC P.O. Box 19928 Alexandria, Virginia 22320 Telephone: (703) 836-6400 DEPOSIT ACCOUNT USE
AUTHORIZATION
Please grant any extension
necessary for entry;
Charge any fee due to our
Deposit Account No. 15-0461

Sheet i oi j	Sheet	1	of 5	
--------------	-------	---	------	--

Form PTO-1449 US Dept. of Comm (REV. 1/06) PATENT & TRADEMARK OF						APPLICAT 10/572,905			
INFORMATION DISCLOSURE STATEMENT									
(Use several sheets if necessary)				APPLICANTS Valerie COMBARET et al.			<u> </u>		
				FILING DATE March 21, 2006					
		U.	S. PATEN	T DOCUM	MENTS		<u></u>		
Examiner Initials	Cite No.	Document Number	Da	te		Name			
	1	5,234,809	08/10/19	93	Boom et al.				
	2	4,672,040	06/09/19	87	Josephson				
	3	5,750,338	05/12/19	98	Collins et al.				
	4	4,683,202	07/28/19	87	Mullis				
	5	5,700,637	12/23/19	97	Southern				
	6	5,445,934	08/29/19	95	Fodor et al.	-			
	7	5,744,305	04/28/19	98	Fodor et al.				
	8	5,807,522	09/15/1998		Brown et al.				
	9	4,683,195	07/28/19	87	Mullis et al.				
	10	4,800,159	01/24/19	89	Mullis et al.			-	
	11	5,399,491	03/21/19	95	Kacian et al.				
	12	4,981,783	01/01/19	91	Augenlicht				
FOREIGN PATENT DOCUMENTS									
Examiner Initials	Cite No.	Document Number	Da	ite	Country		With English Abstract	With English Translation	
	13	FR 2 816 711	05/17/20	002	France				
	14	FR 2 816 958	05/24/20	002	France				
	15	WO 00/05338	02/03/20	000	WIPO		х		
- 4 - 12 - 4	16	WO 99/53304	10/21/19	99	WIPO		Х		
·	17	WO 99/35500	07/15/19	199	WIPO		х		
	18	WO 97/45202	12/04/19	97	WIPO		х		
	19	WO 00/71750 A1	11/30/20	000	WIPO		х		
	20	WO 89/10977	11/16/19	89	WIPO				
		T	OTHER D	OCUME	NTS				
Examiner Initials									
EXAMINER						DATEC	ONSIDERED	1	
Examiner:		citation considered, whether or not citation considered. Include copy of this form with				hrough cit	ation if not in	conformance	

Form PTO-14 (REV. 1/06)				ATTY DOCKET NO. 127189			APPLICATION NO. 10/572,905		
INFORMATION DISCLOSURE STATEMENT								:	
(Use several sheets if necessary)				APPLICANTS Valerie COMBARET et al.					
					DATE 21, 2006				
	V-11*	Ų.	S. PATEN	T DOCUM	1ENTS				
Examiner Initials	Cite No.	Document Number	Da	Date Name					
		FORE	IGN PAT	ENT DOC	CUMENTS T			1777-1	
Examiner Initials	Cite No.	Document Number	Date		Country		With English Abstract	With English Translation	
	21	WO 90/03382	04/05/19	990	WIPO				
	22	WO 91/19812	12/26/19	991	WIPO		x		
-	23	WO 99/65926	12/23/1	999	WIPO		x		
	24	WO 01/44507 A1	06/21/2001		WIPO				
	25	WO 01/44506 A1	06/21/2001		WIPO				
	26	WO 02/090584 A2	11/14/2002		WIPO		х		
,	27	WO 02/090319 A1	11/14/2002		WIPO		х		
	28	WO 90/01069	02/08/1990		WIPO				
	29	WO 90/06995	06/28/1	990	WIPO				
	30	WO 91/02818	03/07/1	991	WIPO				
	31	WO 94/12670	06/09/1	994	WIPO				
-	32	WO 99/15321	04/01/1999		WIPO				
	33	EP 0 201 184 A2	12/17/1	986	Europe				
			OTHER	DOCUME	ENTS				
Examiner Initials	Cite No.	(Including Author, Title, Date, Pertinent Pages, etc.)							
	34	Truckenmiller et al., "Gene Expression Profile in Early Stage of Retinoic Acid-Induced Differentiation of Human SH-SY5Y Neuroblastoma Cells," Restorative Neurology and Neuroscience, Vol. 18, pp. 67-80, September 26, 2001.							
	35	Takita et al., "Gene Expression Profiling and Identification of Novel Prognostic Marker Genes in Neuroblastoma," Genes, Chromosomes & Cancer, Vol. 40, pp. 120-132, 2004.							
	36	Hiyama et al., "Expression Profiling of	of Favorab	le and Uni	favorable Neuroblastomas," Pediat	r Surg Int,	Vol. 20, pp.	33-38, 2004.	
	37	Doh-ura et al., "Identification of Diff Pathogenesis, Vol. 18, pp. 1-9, 1995.		Expressed	Genes in Scrapie-Infected Mouse	Neuroblas	toma Cells,"	Microbial	
	38	Mora et al., "Evolving Significance of Letters, Vol. 197, pp. 119-124, 2003		tic Marker	s Associated with New Treatment	Strategies	in Neuroblas	toma," Cancer	
EXAMINE	R					DATE	CONSIDERE	D	
Examiner:	Initial i	f citation considered, whether or not cita	tion is in	conformar	nce with M.P.E.P. 609; draw line	through ci	tation if not	in conformance	

Form PTO-1449 US Dept. of Commerce (REV. 1/06) PATENT & TRADEMARK OFFICE			ATTY DOCKET NO. APPLICATION N 127189 10/572,905						
INFORMATION DISCLOSURE STATEMENT									
(Use several sheets if necessary)					CANTS COMBARET et al.		1		
				FILING March 2	DATE 21, 2006				
		U.	S. PATEN	L DOCUM	MENTS				
Examiner Initials	Cite No.	Document Number	Da	Date Name					
								· · · · · · · · · · · · · · · · · · ·	
	<u> </u>	FORE	EIGN PATI	ENT DOC	UMENTS T				
Examiner Initials	Cite No.	Document Number	Da	ite	e Country		With English Abstract	With English Translation	
	<u> </u>								
	1		OTHER D	OCUME	NTS				
Examiner Initials	Cite No.	(Including Aut	hor, Title,	Date, Pert	inent Pages, etc.)				
	39	De Preter et al., "Quantification of MYCN, DDXI, and NAG Gene Copy Number in Neuroblastoma Using a Real-Time Quantitative PCR Assay," Modern Pathology, Vol. 15, No. 2, pp. 159-166, 2002.							
	40	Sardi et al., "Molecular Profiling of High-Risk Neuroblastoma by cDNA Array," International Journal of Molecular Medicine, Vol. 9, pp. 541-545, 2002.							
	41	Alaminos et al., "Genome-wide Analysis of Gene Expression Associated with MYCN in Human Neuroblastoma," Cancer Research, Vol. 63, pp. 4538-4546, August 1, 2003.							
	42	Yamanaka et al., "Maturational Sequence of Neuroblastoma Revealed by Molecular Analysis on cDNA Microarrays," International Journal of Oncology, Vol. 21, pp. 803-807, 2002.							
	43	Keller, "Non-Radioactive Labeling Procedures," DNA Probes, Section 5, pp. 173-198, 2 nd Edition, Stockton Press, 1993.							
	44	Manak, "Hybridization Formats and Detection Procedures," DNA Probes, Section 6, pp. 199-253, 2 nd Edition, Stockton Press, 1993.						ton Press,	
	45	Giulietti et al., "An Overview of Real-Time Quantitative PCR: Applications to Quantify Cytokine Gene Expression," Methods, Vol. 25, pp. 386-401, 2001.						Methods,	
-	46	Kricka, "Nucleic Acid Detection Technologies - Labels, Strategies, and Formats," Clinical Chemistry, Vol. 45, No. 4, pp. 453-458, 1999.						, pp. 453-	
	47	Boom et al., "Rapid and Simple Method for Purification of Nucleic Acids," Journal of Clinical Microbiology, Vol. 28, No. 3, pp. 495-503, March 1990.							
	48	Bustin, "Quantification of mRNA Using Real-Time Reverse Transcription PCR (RT-PCR): Trends and Problems," Journal of Molecular Endocrinology, Vol. 29, pp. 23-39, 2002.							
	49	Nielsen et al., "Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted Polyamide," Science, Vol. 254, pp. 1497-1500, December 1991.							
	50	Levison et al., "New Approaches to the Isolation of DNA by Ion-Exchange Chromatography," Journal of Chromatography A, Vol. 827, pp. 337-344, 1998.						raphy A,	
	51	Ramsay, "DNA Chips: State-of-the Ar	t," Nature	Biotechno	ology, Vol. 16, pp. 40-44, January	1998.			
	52	Livache et al., "Preparation of a DNA Oligonucleotides Bearing a Pyrrole Gr							
EXAMINER						DATE	CONSIDERED	•	
Evaminan	Initial if	aitation considered whether or not situt	ion in in ac		no with M.P.E.P. 600: draw line t	hrough oi		aconformana.	

and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 US Dept. of Commerce (REV. 1/06) PATENT & TRADEMARK OFFICE			ATTY DOCKET NO. 127189				APPLICATION NO. 10/572,905		
	INFORMAT	TION DISCLOSURE STATEMENT							
	(Use	e several sheets if necessary)		APPLICANTS Valerie COMBARET et al.					
				FILING March 2					
		U.S.	. PATEN	T DOCUM	IENTS				
Examiner Initials	Cite No.	Document Number	Da	Date Name					
· 									
Examiner Initials	Cite No.	FOREI	ENT DOC	Country	-	With English Abstract	With English Translation		
			OTHER I	OCUME	NTS				
Examiner Initials	Cite No.	(Including Auth	or, Title,	Date, Pert	inent Pages, etc.)				
	53	Berthold et al., "Multivariate Evaluation Hematology/Oncology, Vol. 16, No. 2,	n of Progr pp. 107-1	nostic Fact 115, 1994.	tors in Localized Neuroblastoma,"	The Am	erican Journal	of Pediatric	
	54	Maris et al., "Molecular Biology of Neuroblastoma," Journal of Clinical Oncology, Vol. 17, No. 7, pp. 2264-2279, July 1999.						aly 1999.	
	55	Rubie et al., "N-Myc Gene Amplification Is a Major Prognostic Factor in Localized Neuroblastoma: Results of the French NBL 90 Study," Journal of Clinical Oncology, Vol. 15, No. 3, pp. 1171-1182, March 1997.							
	56	Brodeur et al., "Revisions of the International Criteria for Neuroblastoma Diagnosis, Staging, and Response to Treatment," Journal of Clinical Oncology, Vol. 11, No. 8, pp. 1466-1477, August 1993.							
	57	Laug et al., "Initial Urinary Catecholamine Metabolite Concentrations and Prognosis in Neuroblastoma," Pediatrics, Vol. 62, No. 1, pp. 77-83, July 1978.							
	58	Seeger et al., "Association of Multiple Copies of the N-myc Oncogene with Rapid Progression of Neuroblastomas," The New England Journal of Medicine, Vol. 313, No. 18, pp. 1111-1116, October 1985.							
	59	Ihaka et al., "R: A Language for Data A pp. 299-314, 1996.	haka et al., "R: A Language for Data Analysis and Graphics," Journal of Computational and Graphical Statistics, Vol. 5, No. 3, pp. 299-314, 1996.						
	60	Berthold et al., "Prognostic Factors in Metastatic Neuroblastoma: A Multivariate Analysis of 182 Cases," The American Journ of Pediatric Hematology/Oncology, Vol. 14, No. 3, pp. 207-215, 1992.						ican Journal	
1	61	Evans et al., "Prognostic Factors in Neuroblastoma," Cancer, Vol. 59, pp. 1853-1859, June 1987.							
	62	Tibshirani et al., "Diagnosis of Multiple Cancer Types by Shrunken Centroids of Gene Expression," PNAS, Vol. 99, No. 10, pp. 6567-6572, May 2002.							
	63	Cheng et al., "Microchip-based Devices for Molecular Diagnosis of Genetic Diseases," Molecular Diagnosis, Vol. 1, No. 3, pp. 183-200, 1996.							
	64	Ginot, "Oligonucleotide Micro-Arrays for Identification of Unknown Mutations: How Far from Reality?," Human Mutation, Vol. 10, pp. 1-10, 1997.							
	65	Chee et al., "Accessing Genetic Information with High-Density DNA Arrays," Science, Vol. 274, No. 5287, pp. 610-614, October 1996.							
	66	Pease et al., "Light-generated Oligonucleotide Arrays for Rapid DNA Sequence Analysis," Proc. Natl. Acad. Sci., Vol. 91, pp. 5022-5026, May 1994.							
	67	Cheng et al., "Preparation and Hybridi Nature Biotechnology, Vol. 16, pp. 54	ization Ai	nalysis of lune 1998.	DNA/RNA from E. coli on Microf	âbricated	d Bioelectronic	Chips,"	
EXAMINE	R		4.			DATE	CONSIDERE	D	
Examiner:	Initial i	f citation considered, whether or not citati considered. Include copy of this form wit	ion is in th next co	conformar	nce with M.P.E.P. 609; draw line tion to applicant.	through	citation if not	in conformance	

		ATTY DOCKET NO. APPLICATION NO. 127189 APPLICATION NO. 10/572,905							
INFORMATION DISCLOSURE STATEMENT									
(Use several sheets if necessary)			APPLICANTS Valerie COMBARET et al.						
					DATE 21, 2006			· · · · · · · · · · · · · · · · · · ·	
		U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No.	Document Number	Da				Name		
	-								
		FORE	EIGN PATI	ENT DOC	UMENTS				
Examiner Initials	Cite No.	Document Number	Date		Country		With English Abstract	With English Translation	
		· · · · · · · · · · · · · · · · · · ·							
	OTHER DOCUMENTS								
Examiner Initials	Cite No.	(Including Author, Title, Date, Pertinent Pages, etc.)							
	68	Brodeur, "Neuroblastoma: Biological Insights into a Clinical Enigma," Nature Reviews, Cancer, Vol. 3, pp. 203-216,							
		March 2003.							
	69	Lipshutz et al., "High Density Synthetic Oligonucleotide Arrays," Nature Genetics Supplement, Vol. 21, pp. 20-24,							
		January 1999.							
EXAMINER						DATE C	ONSIDERED		
Examiner:	Initial if c	citation considered, whether or not citationsidered. Include copy of this form with	on is in co	nformanc municatio	e with M.P.E.P. 609; draw line ton to applicant.	hrough cita	ation if not in	conformance	